Nature Communications (Feb 2023)
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
- Jenniffer Linares,
- Anna Sallent-Aragay,
- Jordi Badia-Ramentol,
- Alba Recort-Bascuas,
- Ana Méndez,
- Noemí Manero-Rupérez,
- Daniele Lo Re,
- Elisa I. Rivas,
- Marc Guiu,
- Melissa Zwick,
- Mar Iglesias,
- Carolina Martinez-Ciarpaglini,
- Noelia Tarazona,
- Monica Varese,
- Xavier Hernando-Momblona,
- Adrià Cañellas-Socias,
- Mayra Orrillo,
- Marta Garrido,
- Nadia Saoudi,
- Elena Elez,
- Pilar Navarro,
- Josep Tabernero,
- Roger R. Gomis,
- Eduard Batlle,
- Jorge Pisonero,
- Andres Cervantes,
- Clara Montagut,
- Alexandre Calon
Affiliations
- Jenniffer Linares
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Anna Sallent-Aragay
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Jordi Badia-Ramentol
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Alba Recort-Bascuas
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Ana Méndez
- Department of Physics, Faculty of Science, University of Oviedo
- Noemí Manero-Rupérez
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Daniele Lo Re
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Elisa I. Rivas
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Marc Guiu
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Melissa Zwick
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Mar Iglesias
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Carolina Martinez-Ciarpaglini
- Department of Pathology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia
- Noelia Tarazona
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
- Monica Varese
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Xavier Hernando-Momblona
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Adrià Cañellas-Socias
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Mayra Orrillo
- Medical Oncology Department, Hospital del Mar
- Marta Garrido
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Nadia Saoudi
- Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO)
- Elena Elez
- Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO)
- Pilar Navarro
- Institute of Biomedical Research of Barcelona (IIBB-CSIC)
- Josep Tabernero
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
- Roger R. Gomis
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Eduard Batlle
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST)
- Jorge Pisonero
- Department of Physics, Faculty of Science, University of Oviedo
- Andres Cervantes
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
- Clara Montagut
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Alexandre Calon
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- DOI
- https://doi.org/10.1038/s41467-023-36334-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
Standard platinum-based chemotherapy is the basis of treatment of many cancers, however a proportion of patients do not derive benefit. Here the authors show that the platinum-based drug oxaliplatin accumulates in cancer-associated fibroblasts, activating pathways associated with cancer progression and resistance to therapy.
